Content sits at the heart of customer experience (CX) and is core to commercial transformation and success of life science and healthcare organizations. A great content strategy can create resilient bonds between the brand and the audience. However, life sciences organizations have struggled to build an effective and efficient content strategy that can keep pace with the ever-evolving CX landscape. This is due to:
Customer expectations for omnichannel experiences
Each customer is dynamic and multidimensional; they do not shy away from experiencing new forms of engagement. They expect to be engaged where they are (channels) with the information (content) they need and at a time (cadence) of their convenience. Content strategies on the other hand have remained static, unidimensional, and constrained by archaic processes and systems. As a result, they have failed to fully satisfy the omnichannel expectations of customers.
The evolving role of the patient
Life sciences organizations have mainly focused on honing relationships with healthcare providers (HCPs). They have heavily relied on HCPs to provide insights regarding patient preferences and challenges. However, with a surge in patients consuming medical content through numerous health-focused digital platforms, they have now become active participants in their health journeys. They want to form direct relationships with life sciences organizations and wish to be actively engaged by them. Yet, life sciences organizations have so far failed to deliver.
Uninspired payer reach outs
Payers play a critical role in ensuring that innovative therapies reach patients who need them. Yet, to date, life sciences companies have shied away from engaging them beyond the standard account manager and medical science liaison-driven reach outs. To strengthen their relationship with the payer community and to gain their trust, life sciences organizations need to rethink their payer engagement models. They need to leverage relevant communication channels to demonstrate the value of their drug and communicate their indisputable focus on improving patient outcomes.
These disruptive changes have put tremendous pressure on life sciences’ traditional and human-dependent content supply chain to provide personalized content across channels and geographies. Although several forward-thinking organizations have managed to build capabilities to streamline and scale their content operations, several others have found it hard to keep up, and here’s why.
These challenges have resulted in content redundancies, duplication of effort, significant cost inefficiencies, and, also, negatively impacted the CX delivered. Limited access to data-driven insights to optimize content performance have also prevented marketers from making changes on the go.
So, how can life sciences companies adopt a fast, efficient, and cost-effective approach to deliver personalized content at scale? The answer lies in a technology-led and innovative content supply chain that can keep up with the volume, variety, and velocity of content required to service the diverse channels.
Over the last ten years, Veeva and Indegene have supported numerous life sciences organizations to strengthen their content operations and add value to customer interactions. Their integrated solutions enable the end-to-end digitization of the content supply chain and empower life sciences organizations in their pursuit to provide a personalized experience at scale.
By combining Veeva’s Vault PromoMats for medical, legal, and regulatory (MLR) review, digital asset management (DAM), and modular content with Indegene’s NEXT technology platforms for automated modular content creation, organizations can improve content reuse, accelerate their speed to market for campaigns and drive significant cost savings in the long run.
Indegene's seamless tech architecture maximizes the value of Veeva DAM and accelerates the content life cycle
Plan and extract
Indegene’s NEXT Content Collaboration builds coherent brand, content, and campaign strategies and helps brand teams to initiate workflows and define and track budgets and spending. Following this, the NEXT Commercial Content Intelligence platform extracts and deconstructs content components derived from the existing master content assets and converts them into machine-readable structured data.
Create, review, approve, and store
These harvested and data-enriched components are fed into Veeva Vault PromoMats Digital Asset Management solution. components, approved promotional claims, and other text assets can be combined into content modules, then reviewed and approved through MLR. Approved modules are then sent to Indegene’s NEXT Grid Management platform to build channel-agnostic grids that can be transformed into a multitude of content assets.
Author and deliver
Finally, Indegene’s NEXT Tactic Management platform extracts these modules and grids from Vault PromoMats to create personalized tactics such as emails, banners, and e-detail, using pre-defined templates. These tactics, if all content combinations are pre-approved through MLR in Vault PromoMats, can then be sent to marketing automation platforms for the campaign execution and generation of analytics, driving more refined content personalization.
There are several benefits that life sciences organizations can derive from such a technology-led and machine-driven content supply chain. Some of these include:
We are witnessing a prominent transition toward a new way of doing things in the life sciences’ content operations space. By leveraging Indegene’s and Veeva’s integrated solutions, life sciences organizations will be able to transform their existing content supply chain and achieve exponential personalization of compliant content that cuts through the noise and helps the customer feel connected to the brand.